Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo Ascierto 1, * Michele Vecchio 2 Caroline Robert 3 Andrzej Mackiewicz 4 Vanna Chiarion-Sileni 5 Ana Arance 6 Céleste Lebbé 7 Lars Bastholt 8 Omid Hamid 9 Piotr Rutkowski 10 Catriona Mcneil 11, 12 Claus Garbe 13 Carmen Loquai 14 Brigitte Dreno 15 Luc Thomas 16 Jean-Jacques Grob 17 Gabriella Liszkay 18 Marta Nyakas 19 Ralf Gutzmer 20 Joanna Pikiel 21 Florent Grange 22 Christoph Hoeller 23 Virginia Ferraresi 24 Michael Smylie 25 Dirk Schadendorf 26 Laurent Mortier 27 Inge Svane 28 Delphine Hennicken 29 Anila Qureshi 29 Michele Maio 30
* Corresponding author
Abstract : BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg. METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189. FINDINGS: Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6-42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9-29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6-17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9-13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70-0·99; p=0·04). The most common grade 3-4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs 21 [6%] of 362 patients in the 3 mg/kg group), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis (ten [3%] vs seven [2%]). Treatment-related serious adverse events were reported in 133 (37%) patients in the 10 mg/kg group and 66 (18%) patients in the 3 mg/kg group; four (1%) versus two (<1%) patients died from treatment-related adverse events. INTERPRETATION: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival than did ipilimumab 3 mg/kg, but with increased treatment-related adverse events. Although the treatment landscape for advanced melanoma has changed since this study was initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warrant further assessment.
Document type :
Journal articles
Complete list of metadatas

Cited literature [22 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01807340
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, June 4, 2018 - 4:11:38 PM
Last modification on : Saturday, November 9, 2019 - 8:40:02 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Paolo Ascierto, Michele Vecchio, Caroline Robert, Andrzej Mackiewicz, Vanna Chiarion-Sileni, et al.. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩. ⟨inserm-01807340⟩

Share

Metrics

Record views

160